FibroGen
James Mi has extensive experience in financial management and analysis, currently serving as Director of FP&A - SG&A at FibroGen, Inc. since February 2016, following roles as Associate Director and Senior Manager in Clinical Business Operations and Finance. James Mi began a career at Gilead Sciences, where responsibilities included senior financial analyst roles supporting corporate financial planning and analysis, as well as finance support for various government affairs functions. Prior experience includes a position as an accountant at Jennerex Biotherapeutics and a business analyst role at Shi Tong Wei Chuang, LLC. James Mi holds a Bachelor of Science degree in Managerial Economics from the University of California, Davis.
This person is not in any teams
FibroGen
FibroGen, Inc. is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, the Company's most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase activity in Phase III clinical development for the treatment of anemia in chronic kidney disease (CKD), and is entering Phase III development for anemia in lower risk myelodysplastic syndromes (MDS). The Company has developed Pamrevlumab. Pamrevlumab is a proprietary therapeutic antibody to inhibit the activity of connective tissue growth factor (CTGF), a common factor in chronic fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure.